{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T13:40:00Z","timestamp":1793367600927,"version":"4.5.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T00:00:00Z","timestamp":1741392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T00:00:00Z","timestamp":1741392000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100008127","name":"Universiti Malaysia Sarawak","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100008127","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pediatr"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Histiocytic sarcoma as a secondary malignancy following childhood leukemia is extremely uncommon with fewer than 20 cases reported worldwide. They often pose a diagnostic challenge and prognosis is dismal. There is a lack of well-established clinical treatment protocols owing to rarity of disease. Majority were managed with chemotherapy with variable outcomes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Case presentation<\/jats:title>\n            <jats:p>Herein we report a rare case of an 8-year-old girl with secondary BRAF<jats:sup>V600<\/jats:sup>-mutant histiocytic sarcoma following T-cell acute lymphoblastic leukemia. After poor disease control with salvage chemotherapy, she was treated with MAPK-targeted therapy with dabrafenib and trametinib. She demonstrated excellent response and remained in partial remission with no signs of disease progression 3 years later.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>There is yet to be consensus on the optimal management for this neoplasm. Description of our successful clinical experience highlights that investigation for BRAF mutations in histiocytic sarcoma is potentially advantageous. It also adds to the growing evidence that precision medicine may be a promising avenue to target this aggressive tumor and lays the foundation for future research.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12887-025-05539-2","type":"journal-article","created":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T06:28:36Z","timestamp":1741415316000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["An 8-year-old girl with secondary histiocytic sarcoma with BRAFV600 mutation following T-cell acute lymphoblastic leukemia demonstrating stable disease for 3 years on dabrafenib and trametinib \u2013 a case report and literature review"],"prefix":"10.1186","volume":"25","author":[{"given":"Sue Lyn","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betty Lee Sue","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting Ting","family":"Yew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dahziela","family":"Yunus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,8]]},"reference":[{"issue":"7","key":"5539_CR1","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, et al. The 5th edition of the world health organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia. 2022;36(7):1703\u201319. https:\/\/doi.org\/10.1038\/s41375-022-01613-1.","journal-title":"Leukemia"},{"issue":"9","key":"5539_CR2","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1002\/pbc.25523","volume":"62","author":"J Alten","year":"2015","unstructured":"Alten J, Klapper W, Leuschner I, Eckert C, Beier R, Vallo E, Krause M, Claviez A, Vieth S, Bleckmann K, M\u00f6ricke A. Secondary Histiocytic sarcoma May cause apparent persistence or recurrence of minimal residual disease in childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2015;62(9):1656\u201360.","journal-title":"Pediatr Blood Cancer"},{"issue":"10","key":"5539_CR3","doi-asserted-by":"publisher","first-page":"e427","DOI":"10.1016\/j.clml.2018.07.286","volume":"18","author":"DR Broadwater","year":"2018","unstructured":"Broadwater DR, Conant JL, Czuchlewski DR, Hall JM, Wei S, Siegal GP, Peker D. Clinicopathologic features and clinical outcome differences in de Novo versus secondary Histiocytic sarcomas: a multi-institutional experience and review of the literature. Clin Lymphoma Myeloma Leuk. 2018;18(10):e427\u201335.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"5539_CR4","doi-asserted-by":"crossref","unstructured":"Soslow RA, Davis RE, Warnke RA, Cleary ML, Kamel OW. True Histiocytic lymphoma following therapy for lymphoblastic neoplasms. Blood. 1996 June;87(12):5207\u201312.","DOI":"10.1182\/blood.V87.12.5207.bloodjournal87125207"},{"issue":"1","key":"5539_CR5","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1002\/mpo.10056","volume":"40","author":"M Wongchanchailert","year":"2003","unstructured":"Wongchanchailert M, Laosombat V. True Histiocytic lymphoma following acute lymphoblastic leukemia. Med Pediatr Oncol. 2003;40(1):51\u20133.","journal-title":"Med Pediatr Oncol"},{"issue":"4","key":"5539_CR6","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/S1470-2045(04)01428-7","volume":"5","author":"AL Feldman","year":"2004","unstructured":"Feldman AL, Minniti C, Santi M, Downing JR, Raffeld M, Jaffe ES. Histiocytic sarcoma after acute lymphoblastic leukaemia: a common clonal origin. Lancet Oncol. 2004;5(4):248\u201350.","journal-title":"Lancet Oncol"},{"issue":"3","key":"5539_CR7","doi-asserted-by":"publisher","first-page":"225","DOI":"10.2350\/09-03-0622-OA.1","volume":"13","author":"EC Castro","year":"2010","unstructured":"Castro EC, Blazquez C, Boyd J, Correa H, De Chadarevian JP, Felgar RE, Graf N, Levy N, Lowe EJ, Manning JT Jr, Proytcheva MA. Clinicopathologic features of Histiocytic lesions following ALL, with a review of the literature. Pediatr Dev Pathol. 2010;13(3):225\u201337.","journal-title":"Pediatr Dev Pathol"},{"issue":"2","key":"5539_CR8","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1002\/pbc.22810","volume":"56","author":"R Kumar","year":"2011","unstructured":"Kumar R, Khan SP, Joshi DD, Shaw GR, Ketterling RP, Feldman AL. Pediatric Histiocytic sarcoma clonally related to precursor B-cell acute lymphoblastic leukemia with homozygous deletion of CDKN2A encoding p16INK4A. Pediatr Blood Cancer. 2011;56(2):307\u201310.","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"5539_CR9","first-page":"267","volume":"3","author":"Z Karabov\u00e1","year":"2013","unstructured":"Karabov\u00e1 Z, Ilievov\u00e1 L. Palliative care in the home: a case study of secondary Histiocytic sarcoma in a 3-year-old child. J Health Sci. 2013;3(3):267\u201370.","journal-title":"J Health Sci"},{"issue":"10","key":"5539_CR10","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1038\/sj.leu.2403075","volume":"17","author":"JH Dalle","year":"2003","unstructured":"Dalle JH, Leblond P, Decouvelaere A, Yakoub-Agha I, Preudhomme C, Nelken B, Mazingue F. Efficacy of thalidomide in a child with Histiocytic sarcoma following allogeneic bone marrow tranplantation for T-ALL. Leukemia. 2003;17(10):2056\u20137.","journal-title":"Leukemia"},{"issue":"1","key":"5539_CR11","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1080\/08880018.2020.1811438","volume":"38","author":"ET Valera","year":"2020","unstructured":"Valera ET, Brassesco MS, Reis MB, Maggioni G, Guerino-Cunha RL, Grecco CE Jr, Kato JE, Tone M. Short-term response to alemtuzumab in CD52-positive secondary Histiocytic sarcoma in a child: is it time to consider new targets? Pediatr Hematol Oncol. 2020;38(1):89\u201396.","journal-title":"Pediatr Hematol Oncol"},{"key":"5539_CR12","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s12288-014-0375-3","volume":"30","author":"AP Ganapule","year":"2014","unstructured":"Ganapule AP, Gupta M, Kokil G, Viswabandya A. Histiocytic sarcoma with acute lymphoblastic leukemia a rare association: case report and literature review. Indian J Hematol Blood Transfus. 2014;30:305\u20138.","journal-title":"Indian J Hematol Blood Transfus"},{"issue":"5","key":"5539_CR13","doi-asserted-by":"publisher","first-page":"e28200","DOI":"10.1002\/pbc.28200","volume":"67","author":"V Venkataraman","year":"2020","unstructured":"Venkataraman V, Massoth LR, Sullivan RJ, Friedmann AM. Secondary Histiocytic sarcoma with BRAFV600E mutation after T-cell acute lymphoblastic leukemia in a very young child with dramatic response to Dabrafenib and Trametinib. Pediatr Blood Cancer. 2020;67(5):e28200.","journal-title":"Pediatr Blood Cancer"},{"issue":"10","key":"5539_CR14","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1002\/pbc.25100","volume":"61","author":"JL Heath","year":"2014","unstructured":"Heath JL, Burgett SE, Gaca AM, Jaffe R, Wechsler DS. Successful treatment of pediatric Histiocytic sarcoma using abbreviated high-risk leukemia chemotherapy. Pediatr Blood Cancer. 2014;61(10):1874\u20136.","journal-title":"Pediatr Blood Cancer"},{"issue":"33","key":"5539_CR15","doi-asserted-by":"publisher","first-page":"3895","DOI":"10.1200\/JCO.20.00762","volume":"38","author":"AK Salama","year":"2020","unstructured":"Salama AK, Li S, Macrae ER, Park JI, Mitchell EP, Zwiebel JA, Chen HX, Gray RJ, McShane LM, Rubinstein LV, Patton D. Dabrafenib and Trametinib in patients with tumors with BRAFV600E mutations: results of the NCI-MATCH trial subprotocol H. J Clin Oncol. 2020;38(33):3895\u2013904.","journal-title":"J Clin Oncol"},{"issue":"6892","key":"5539_CR16","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/nature00766","volume":"417","author":"H Davies","year":"2002","unstructured":"Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949\u201354.","journal-title":"Nature"},{"issue":"1","key":"5539_CR17","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1056\/NEJMoa1412690","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, Lichinitser M, Dummer R, Grange F, Mortier L, Chiarion-Sileni V. Improved overall survival in melanoma with combined Dabrafenib and Trametinib. N Engl J Med. 2015;372(1):30\u20139.","journal-title":"N Engl J Med"},{"issue":"7","key":"5539_CR18","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/S1470-2045(16)30146-2","volume":"17","author":"D Planchard","year":"2016","unstructured":"Planchard D, Besse B, Groen HJ, Souquet PJ, Quoix E, Baik CS, Barlesi F, Kim TM, Mazieres J, Novello S, Rigas JR. Dabrafenib plus Trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. Lancet Oncol. 2016;17(7):984\u201393.","journal-title":"Lancet Oncol"},{"key":"5539_CR19","doi-asserted-by":"crossref","unstructured":"Subbiah V, Kreitman RJ, Wainberg ZA et al. Dabrafenib plus Trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study. Annals of oncology. 2022;33(4):406\u201315.","DOI":"10.1016\/j.annonc.2021.12.014"},{"issue":"15","key":"5539_CR20","doi-asserted-by":"publisher","first-page":"3806","DOI":"10.1182\/bloodadvances.2022008414","volume":"7","author":"JA Whitlock","year":"2023","unstructured":"Whitlock JA, Geoerger B, Dunkel IJ, Roughton M, Choi J, Osterloh L, Russo M, Hargrave D. Dabrafenib, alone or in combination with Trametinib, in BRAF V600\u2013mutated pediatric Langerhans cell histiocytosis. Blood Adv. 2023;7(15):3806\u201315.","journal-title":"Blood Adv"},{"issue":"58","key":"5539_CR21","doi-asserted-by":"publisher","first-page":"98723","DOI":"10.18632\/oncotarget.21920","volume":"8","author":"J Shimono","year":"2017","unstructured":"Shimono J, Miyoshi H, Arakawa F, et al. Prognostic factors for Histiocytic and dendritic cell neoplasms. Oncotarget. 2017;8(58):98723\u201332.","journal-title":"Oncotarget"}],"container-title":["BMC Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-025-05539-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12887-025-05539-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-025-05539-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T10:04:08Z","timestamp":1741601048000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpediatr.biomedcentral.com\/articles\/10.1186\/s12887-025-05539-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,8]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5539"],"URL":"https:\/\/doi.org\/10.1186\/s12887-025-05539-2","relation":{},"ISSN":["1471-2431"],"issn-type":[{"value":"1471-2431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,8]]},"assertion":[{"value":"17 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"NA.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent for publication of the patient\u2019s clinical details and investigation results was obtained from the patient\u2019s parents.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"178"}}